Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
In the past decade, tumor necrosis factor-alpha ( TNF -α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin ( IL )-12/23 inhibitor Stelara have been leading the psoriasis biologics market. However, the recent wave of approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), and Eli Lilly’s Taltz (2016)—is anticipated to substantially alter the market landscape. The oral agent Otezla has been successfully carving out a space in the psoriasis treatment algorithm in biologics-naive patients. The more-effective biologics, IL -17 inhibitors Cosentyx and Taltz, are threatening the first-line dominance of TNF -α inhibitors. With the recent and anticipated entry of biosimilars, marketers of psoriasis therapies will learn how they can best overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.
What are the current patient-share leaders among psoriasis biologics/Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?
How do payers cover/anticipate covering biosimilar versions of infliximab (Pfizer’s Inflectra) and adalimumab (Amgen’s Amgevita), and what are physicians’ expected prescribing behaviors for biosimilars?
What are physician perceptions of emerging biologics, such as brodalumab and guselkumab, and how do payers anticipate covering these novel agents?
What pharmacoeconomic models and data do payers value for examining the cost and efficacy impact of novel psoriasis agents?
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.